A cure for type 1 diabetes
Read about the novel clinical study.
Diabetes researcher Denis Faustman, MD, PhD and colleagues at Massachusetts General Hospital (MGH) are using Mercodia´s C-Peptide kits in a novel type 1 diabetes clinical study.
The trial is testing whether using a generic drug to temporarily elevate tumor necrosis factor-alpha (TNF-a) levels in the body will reduce or eliminate autoimmune T cells in patients with established type 1 diabetes, an approach based on the Faustman lab’s previous success in reversing end-stage diabetes in mice. To learn more, please visit www.faustmanlab.org www.faustmanlab.org
Additional Links of Interest
Listen as Dr. Faustman describes her own research in "EFTR: Targeting Diabetes with an Old TB Vaccine"